Search 

Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 10 own operational offices in Bulgaria, Czech Republic, Georgia, Hungary, India, Kazakhstan, Latvia, Lithuania, Estonia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine.
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.

gloria

Golden State Green World LLC, is a CBG Hemp Cultivator, located in Riverside County, California. Our team has ten years of extensive greenhouse design and a diverse growing experience. We apply our grow methodologies and eco-agricultural knowledge to supply the global market with high quality, contaminant-free, organic CBG enriched hemp products. Our vision is to become a global distributor of organic CBG infused products that will provided medical and therapeutically benefits to the end user.

Early cancer detection company

Guangdong Fengle Group Co., Ltd. (hereinafter referred to as “Fengle Group”), established in 2004, is a diversified and comprehensive industrial group corporation integrated of industry, commerce and Finance.
Fengle Group focuses on energy, new energy, energy conservation and environmental protection, industrial investment and holding, and supply chain finance, optimizing strategic layout and business structure.
Fengle group joined new fields of urban renewal, rural revitalization, medical technology, modern agriculture and animal husbandry etc. while expanding its traditional businesses.
Fengle Group headquartered in Zengcheng district, Guangzhou, then set up five management headquarters in South China, North China, East China, Southwest and Northwest China, achieving nationalization of region and products.
Fengle Group operates in more than 10 countries and regions and creates an annual output value of more than 10 billion yuan.
Guangzhou Fengle Medical Technology Co., Ltd. was founded by the parent company Guangdong Fengle Group Co.,Ltd. The face mask plant of Fengle Medical covers an area of 15,000 square meters, equipped with automatic mask production equipment, automatic packaging equipment, inspection and testing equipment.
Fengle Medical has been established with fine industry, adhering to the philosophy of value discovery, innovation and enlightenment, dedication and altruism, people-oriented, harmony and honesty, cooperation and sharing, innovation and win-win. It provides customers with a full range of quality and value-added services to achieve customer satisfaction, company satisfaction, social satisfaction. Due to rigorous, scientific, efficient and reasonable management system, the company's operation is more standardized, that become a leader in the local industry, developing steadily, rapidly and efficiently.
At present, the company's main products are: Disposable protective masks, disposable children's masks, disposable medical masks, medical surgical masks, KN95 protective masks etc. All the products have obtained the full performance Inspection and Test Report, in line with the relevant national standards and requirements. The company has obtained the ISO 13485 quality system certification, obtained the European Union CE certification, the United States FDA listing for the record, and listed in the "China Chamber of Commerce for Import and Export of Medicines and Health Products Double White List".
Health care is a sunrise industry forever. Fengle Group will take Fengle Medical Technology Co., Ltd as the starting point to build a comprehensive and integrated medical health industry base in the region by connecting with Zhongguancun and the provincial venture capital medical devices, classification diagnosis and treatment, remote diagnosis, health, research and development, and venture capital big data resources.

Guoqian Medical Technology (Suzhou) Co., Ltd. was registered and established in Suzhou High-tech Zone in 2017.

Guoqian Medical has two business platforms: Guoqian Venture Capital and Guoqian Medical Technology Innovation Research Institute.

Guoqian Venture Capital is a professional and market-oriented venture capital institution that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on high-end scientific and technological talents with Chinese major talent engineering experts as the core, they seek high-quality investment targets during the transformation of scientific and technological achievements, the introduction of technological projects, the evaluation of innovative and entrepreneurial projects, and the landing of innovative and entrepreneurial projects.

Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in the domestic medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.

Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.

Angine Biotech (Angine) is a international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building. We are working with our overseas' business partner to introduce the clinical and market unmet projects/products to China by leveraging the local expertise and resources. 

With the professional international BD team, the expert consultant group as well as the valuable data room for Chinese markets in the biotech and health care field, Angine is committed to provide the tailor-made solutions for the overseas’ partners who would like to explore the access to the Chinese markets. The solutions are including but not limited to the Chinese market landscape investigation, the regulatory affairs support, the reimbursement policy study, the ideal incubator and strategic biz partner recommendation, as well as the capital and talent services when the project is confirmed to settle in the referred incubator or campus.

Angine would like work with you as a strategic partner to co-develop the Chinese healthcare market, to make your ideas or IP become the products by inputting the expertise from both sides.

You can write an email to leoluo@anginebio.com for your ideas and proposals for the Chinese markets. Let our team give you a solution.

focUnited States on healthcare

Cross border life science accelerator and angel investor based in San Francisco Bay Area and Wuxi, China.